Keywords: Pancreatic cancer, Market forecast, Eli Lilly, Gemzar, FOLFIRINOX, Celgene, Abraxane, Decision Resources

Increased uptake of FOLFIRINOX and launch of Abraxane will see dynamic change in treatment of pancreatic cancer patients

Article | 23 November 2010

Print This

Although the pancreatic cancer drug market will remain relatively flat through 2019 in the leading markets - the USA, France, Germany, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in